CN115501305A - Traditional Chinese medicine composition for treating liver depression and spleen deficiency damp excess type depression and application thereof - Google Patents
Traditional Chinese medicine composition for treating liver depression and spleen deficiency damp excess type depression and application thereof Download PDFInfo
- Publication number
- CN115501305A CN115501305A CN202211310613.6A CN202211310613A CN115501305A CN 115501305 A CN115501305 A CN 115501305A CN 202211310613 A CN202211310613 A CN 202211310613A CN 115501305 A CN115501305 A CN 115501305A
- Authority
- CN
- China
- Prior art keywords
- portions
- depression
- traditional chinese
- parts
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 119
- 210000004185 liver Anatomy 0.000 title claims abstract description 65
- 210000000952 spleen Anatomy 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 230000007812 deficiency Effects 0.000 title claims abstract description 34
- 238000011282 treatment Methods 0.000 claims abstract description 49
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 18
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 18
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 18
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 18
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 18
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 18
- 244000183685 Citrus aurantium Species 0.000 claims abstract description 17
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 17
- 241000237502 Ostreidae Species 0.000 claims abstract description 17
- 235000020636 oyster Nutrition 0.000 claims abstract description 17
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 16
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 16
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 16
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 244000061520 Angelica archangelica Species 0.000 claims abstract description 6
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims abstract description 6
- 235000017491 Bambusa tulda Nutrition 0.000 claims abstract description 6
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 6
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims abstract description 6
- 244000236658 Paeonia lactiflora Species 0.000 claims abstract description 6
- 244000082204 Phyllostachys viridis Species 0.000 claims abstract description 6
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims abstract description 6
- 239000011425 bamboo Substances 0.000 claims abstract description 6
- 235000001188 Peltandra virginica Nutrition 0.000 claims abstract description 5
- 210000000232 gallbladder Anatomy 0.000 claims description 39
- 210000002784 stomach Anatomy 0.000 claims description 31
- 206010062717 Increased upper airway secretion Diseases 0.000 claims description 29
- 208000026435 phlegm Diseases 0.000 claims description 29
- 239000000463 material Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 244000197580 Poria cocos Species 0.000 claims description 17
- 210000000988 bone and bone Anatomy 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 15
- 241000382455 Angelica sinensis Species 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 206010003591 Ataxia Diseases 0.000 claims description 7
- 206010010947 Coordination abnormal Diseases 0.000 claims description 7
- 208000016290 incoordination Diseases 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 208000020401 Depressive disease Diseases 0.000 claims description 6
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 5
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 241000244155 Taenia Species 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 235000008504 concentrate Nutrition 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- -1 decoction Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 49
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 229940126673 western medicines Drugs 0.000 abstract description 2
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 45
- 208000011580 syndromic disease Diseases 0.000 description 24
- 229940079593 drug Drugs 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 15
- 238000003745 diagnosis Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 208000019901 Anxiety disease Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 230000036506 anxiety Effects 0.000 description 11
- 230000009467 reduction Effects 0.000 description 10
- 241001522129 Pinellia Species 0.000 description 9
- 230000002354 daily effect Effects 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 8
- 238000010792 warming Methods 0.000 description 8
- 208000001431 Psychomotor Agitation Diseases 0.000 description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 238000012346 open field test Methods 0.000 description 7
- 239000006187 pill Substances 0.000 description 7
- 206010067484 Adverse reaction Diseases 0.000 description 6
- 206010022998 Irritability Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 206010038743 Restlessness Diseases 0.000 description 6
- 230000006838 adverse reaction Effects 0.000 description 6
- 239000009752 danzhi xiaoyao Substances 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 206010000060 Abdominal distension Diseases 0.000 description 5
- 241000132012 Atractylodes Species 0.000 description 5
- 206010010144 Completed suicide Diseases 0.000 description 5
- 206010012374 Depressed mood Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 208000000044 Amnesia Diseases 0.000 description 4
- 208000031091 Amnestic disease Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 208000007882 Gastritis Diseases 0.000 description 4
- 208000004356 Hysteria Diseases 0.000 description 4
- 230000006986 amnesia Effects 0.000 description 4
- 230000001174 ascending effect Effects 0.000 description 4
- 208000012839 conversion disease Diseases 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 3
- 206010011469 Crying Diseases 0.000 description 3
- 206010011971 Decreased interest Diseases 0.000 description 3
- 235000018958 Gardenia augusta Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002618 waking effect Effects 0.000 description 3
- AHOUBRCZNHFOSL-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000031361 Hiccup Diseases 0.000 description 2
- 206010049976 Impatience Diseases 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- 206010029333 Neurosis Diseases 0.000 description 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 2
- 240000005001 Paeonia suffruticosa Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010042458 Suicidal ideation Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 208000023652 chronic gastritis Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002898 effect on depression Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 208000015238 neurotic disease Diseases 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 201000000484 premenstrual tension Diseases 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical group O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 235000010685 Agastache foeniculum Nutrition 0.000 description 1
- 244000180303 Agastache foeniculum Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000235503 Glomus Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 201000001916 Hypochondriasis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000027626 Neurocognitive disease Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241001106477 Paeoniaceae Species 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 206010037213 Psychomotor retardation Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003866 digestant Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000012048 forced swim test Methods 0.000 description 1
- 239000009519 fu-yuan Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960005183 paroxetine hydrochloride Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 239000010389 wendan Substances 0.000 description 1
- 239000008539 xiaoyao Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Marine Sciences & Fisheries (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 6 to 20 portions of rhizoma pinelliae preparata, 6 to 20 portions of radix bupleuri, 6 to 20 portions of white peony root, 6 to 20 portions of bamboo shavings, 6 to 30 portions of immature bitter orange, 6 to 30 portions of fried rhizoma atractylodis macrocephalae, 6 to 20 portions of angelica, 6 to 20 portions of moutan bark, 6 to 20 portions of gardenia, 6 to 20 portions of dried orange peel, 6 to 20 portions of tuckahoe, 9 to 30 portions of keel, 9 to 30 portions of oyster, 3 to 15 portions of mint and 6 to 20 portions of honey-fried licorice root. The traditional Chinese medicine composition provided by the invention is safe, quick in effect, good in treatment effect, free of toxic and side effects, easy to accept by patients, and capable of avoiding toxic and side effects caused by large-dose use of western medicines.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, particularly discloses a traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness, and particularly relates to a traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness, and a preparation method and application thereof.
Background
Depression belongs to mood disorder, also known as depressive disorder or depressive episode, and is a disease with mood depression as a main symptom caused by various reasons, patients often have loss of interest, guilt feeling, attention difficulty, loss of appetite and suicidal ideation, and other abnormalities of cognitive, behavior and social functions. The depression belongs to global high-grade mental diseases, has the characteristics of high morbidity, high disability rate, high suicide rate and high recurrence rate, and brings serious social and economic burden. With the increasing social competition and the increasing living pressure, the prevalence rate of depression is on the rising trend year by year, and the affected people tend to be younger. The World Health Organization (WHO) report in 2017 shows that up to 3.22 million people worldwide suffer from depression, the prevalence rate is about 4.4%, and nearly 80 million suicide deaths per year will be the second largest disease after cardiovascular diseases.
At present, oral antidepressant drugs are taken as the main treatment for depression, and although depression symptoms can be relieved, the oral antidepressant drugs have the problems of high recurrence rate, long medication period, poor patient compliance, great side effect, even possible suicide tendency and the like. How to effectively improve the treatment effect of depression has become a great problem to be solved urgently in the field at present. The traditional Chinese medicine is based on holism concept and treatment based on syndrome differentiation, can effectively improve clinical symptoms of depression patients, improves the life quality of the depression patients, and has the unique advantages of stable curative effect, low recurrence rate, less side effect, good patient compliance and the like in the aspect of preventing and treating depression. The commonly used Chinese patent medicines for treating depression in the current market comprise: pill for relieving stagnation of qi and liver, bupleuri radix pill for relieving liver qi, capsule for relieving stagnation of qi, XIAOYAO pill, JIEYU pill, YUJU pill, etc. The product has two defects: 1. the efficacy is insufficient, the healthy qi is damaged by excessive purgation, the effect is single to treat the symptoms and not the root causes, or the effect is mild and the medicine taking period is too long; 2. the dosage form is insufficient, mostly pills, but slow and slow in the case of pills, hinder the curative effect of the medicine.
Therefore, it is necessary to develop a Chinese medicinal composition with good and quick effect for treating depression.
Disclosure of Invention
In view of the above technical problems, the present invention provides the following technical solutions:
the invention provides a traditional Chinese medicine composition for treating liver depression and spleen deficiency and excessive dampness type depression, which is prepared from the following raw materials in parts by weight: 6 to 20 portions of rhizoma pinelliae preparata, 6 to 20 portions of radix bupleuri, 6 to 20 portions of white peony root, 6 to 20 portions of bamboo shavings, 6 to 30 portions of immature bitter orange, 6 to 30 portions of fried rhizoma atractylodis macrocephalae, 6 to 20 portions of angelica, 6 to 20 portions of moutan bark, 6 to 20 portions of gardenia, 6 to 20 portions of dried orange peel, 6 to 20 portions of tuckahoe, 9 to 30 portions of dragon bone, 9 to 30 portions of oyster, 3 to 15 portions of mint and 6 to 20 portions of honey-fried licorice root.
Preferably, the feed additive is prepared from the following raw materials in parts by weight: 15 parts of rhizoma pinelliae preparata, 10 parts of radix bupleuri, 15 parts of radix paeoniae alba, 15 parts of caulis bambusae in taeniam, 20 parts of immature bitter orange, 20 parts of fried rhizoma atractylodis macrocephalae, 10 parts of angelica sinensis, 15 parts of cortex moutan radicis, 10 parts of fructus gardeniae, 20 parts of pericarpium citri reticulatae, 15 parts of poria cocos, 30 parts of dragon bone, 30 parts of oyster, 6 parts of mint and 10 parts of honey-fried licorice root.
The second aspect of the invention provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps:
weighing rhizoma Pinelliae, bupleuri radix, radix Paeoniae alba, caulis Bambusae in Taenia, fructus Aurantii Immaturus, parched Atractylodis rhizoma, radix Angelicae sinensis, cortex moutan, fructus Gardeniae, pericarpium Citri Tangerinae, poria, os Draconis, concha Ostreae, herba Menthae and radix Glycyrrhizae Preparata in parts by weight;
decocting the weighed medicinal materials in water, and collecting decoction to obtain the traditional Chinese medicine composition.
Preferably, the specific operation process of decocting with water comprises the following steps: adding water which is 6 to 8 times of the total amount of the medicinal materials into the mixed medicinal materials, decocting for 2 to 3 times, 1.0 to 1.5 hours each time, combining the decoction, and filtering.
The third aspect of the invention provides application of the traditional Chinese medicine composition in preparing a medicine for treating depression.
Preferably, the depression is caused by liver depression and spleen deficiency, incoordination between gallbladder and stomach, phlegm dampness and stasis.
The fourth aspect of the invention provides a medicament for treating depression, which comprises the traditional Chinese medicine composition and pharmaceutically acceptable auxiliary materials or carriers.
Preferably, the dosage form of the medicine is granules, tablets, decoction, capsules or syrup.
The fifth aspect of the invention provides traditional Chinese medicine granules for treating depression caused by liver depression and spleen deficiency and excessive dampness, which comprise the traditional Chinese medicine composition and pharmaceutically acceptable auxiliary materials.
The sixth aspect of the invention provides a preparation method of the traditional Chinese medicine granules, which comprises the following steps:
weighing rhizoma Pinelliae, bupleuri radix, radix Paeoniae alba, caulis Bambusae in Taenia, fructus Aurantii Immaturus, parched Atractylodis rhizoma, radix Angelicae sinensis, cortex moutan, fructus Gardeniae, pericarpium Citri Tangerinae, poria, os Draconis, concha Ostreae, herba Menthae and radix Glycyrrhizae Preparata according to weight parts;
mixing the weighed medicinal materials, adding water, decocting, collecting decoction, concentrating at 50 deg.C and-0.06-0.08 mpa, adding sugar powder and soluble starch into the obtained concentrate, granulating, drying, and grading.
The depression belongs to the category of depression syndrome in the traditional Chinese medicine, and the clinical syndromes can be classified into kidney deficiency and liver depression syndrome, liver depression and spleen deficiency syndrome, heart and kidney imbalance syndrome, liver and gallbladder dampness-heat syndrome and heart and gallbladder qi deficiency syndrome according to the 'Chinese medicine syndrome diagnosis standard and treatment scheme for depression'. The first depression syndrome in the international guideline for clinical practice of Chinese medicine, first depression, is characterized by liver-qi stagnation, liver-qi stagnation and spleen deficiency, deficiency of both heart and spleen, kidney deficiency and liver depression, and damp-heat in liver and gallbladder.
The traditional Chinese medicine composition provided by the invention treats depression by integrating liver, gallbladder, spleen and stomach. Liver governing smoothing flow of qi and gallbladder governing making decisions, regulating qi movement of the whole body; the spleen and stomach are located in the middle energizer and the qi movement of the whole body is the pivotal point of ascending and descending. The liver, gallbladder and spleen and stomach play an important role in qi movement, and the smooth movement of qi depends on the smoothing of flow of liver and gallbladder and the ascending, clear and descending of spleen and stomach. Lidongyuan pays great attention to the hair-growing function of gallbladder qi, and thinks that the hair-growing gases of gallbladder and stomach depend on each other and are mutually used, so that they are good and good at all times and are damaged at all times. If the spleen and stomach are weak, the gallbladder qi will not rise; however, the ascending of stomach qi will be affected by the failure of gallbladder qi to ascend. He says in the theory of spleen and stomach and the transmission and transformation of deficiency and excess of spleen and stomach: for gallbladder, qi is generated in spring, and in spring, qi is transformed into various things, so that the gallbladder qi is generated in spring, and the rest of the zang-organs are derived. "in lan ventricular secret storage-spleen and kidney deficiency theory" proposed: when people eat food, they can get into the stomach and the nutritive qi rises, i.e. qi of the gallbladder of shaoyang nail. ". Prolonged loss of liver qi, liver disease transmitting spleen, spleen failing to transport and transform, phlegm turbidity, phlegm-fire combining with qi ascending and descending, up-going disturbing the heart, and mental dysfunction, which may be manifested as anxiety, irritability, emotional runaway, and even mania, disturbing the flow of the mind. If the liver fails to dredge and the spleen fails to transport and transform, phlegm-heat will disturb the interior and the gallbladder will ascend and disorder, resulting in the reduction of anxiety and resolution, and the symptoms of timidity, anxiety, fear and fright will occur.
The traditional Chinese medicine composition provided by the invention takes 'liver and spleen concordance, phlegm elimination and dampness elimination, middle regulation and nerve soothing' as an entry point for treatment, takes the Jiawei Xiaoyao powder from Ming & Xue Ji's internal medicine Abstract and the Song & Chen's Henbao from the gallbladder-warming decoction from the Sanyin Ji Yi Bing Lun, and is added with dragon bone and oyster, the Jiawei Xiaoyao powder has the effects of soothing the liver, strengthening the spleen, clearing heat, nourishing blood, regulating qi, eliminating phlegm, clearing gallbladder and harmonizing the stomach. The liver and gallbladder, spleen and stomach are both zang-fu organs and are both exterior and interior, the liver and spleen are regulated by treating viscera, the gallbladder-warming decoction is combined with gallbladder and stomach, the liver and gallbladder are soothing, gallbladder qi is benefited, the liver and gallbladder are cleared to relieve liver depression, the spleen and stomach are benefited, the stomach is benefited to lower, the spleen and stomach are helped to ascend, viscera diseases are treated simultaneously, the effects of soothing the liver, strengthening the spleen, clearing the gallbladder and stomach are more excellent, and the dragon bone and oyster are added for tranquilization, so the traditional Chinese medicine is especially suitable for people with depression, liver depression, spleen deficiency, incoordination between gallbladder and stomach, and phlegm-dampness stasis. In the formula, radix bupleuri is used for soothing liver and relieving depression, pinellia tuber is used for eliminating dampness and phlegm, harmonizing stomach and descending adverse qi, and is used as a monarch drug, radix bupleuri is used for soothing liver and relieving depression to regulate liver qi, pinellia tuber is used for eliminating phlegm and descending adverse qi to regulate the middle energizer, the radix bupleuri and the pinellia tuber are matched, the liver qi regulation and the middle energizer are regulated to smooth qi movement of the whole body, the radix bupleuri can raise the clear yang of the spleen and the stomach, the pinellia tuber can lower the turbid qi of the middle energizer, and the radix bupleuri and the pinellia tuber are matched to have the effects of raising the clear yang of the spleen and the stomach and lowering the clear qi of the middle energizer; 4 medicines of white paeony root, bamboo shavings, immature bitter orange and fried largehead atractylodes rhizome are taken as ministerial medicines; radix Paeoniae alba, sour, bitter and slightly cold, nourishing blood and astringing yin, and softening liver to relieve spasm, is combined with chai Hu to tonify liver and help liver, blood harmonizes the liver, and blood nourishes the liver to soften the liver, so that the liver body is soft and liver qi is smooth; the caulis bambusae in taeniam has the effects of clearing gallbladder and harmonizing stomach, clearing heat and eliminating phlegm, relieving restlessness and preventing vomiting, and can not only resolve phlegm and harmonize stomach, but also clear gallbladder heat so as to clear and purify gallbladder qi, so that phlegm heat is removed and gallbladder qi is fixed when the caulis bambusae in taeniam is matched with pinellia ternate; the immature bitter orange breaks qi to eliminate stagnation, reduces phlegm and disperses glomus, is matched with the radix bupleuri to ascend and descend and enhance the functions of regulating qi and relieving depression, and is matched with the pinellia tuber for enhancing the effects of regulating qi and reducing phlegm; the stir-fried white atractylodes rhizome has the effects of tonifying spleen and qi, liver diseases are most prone to transmitting spleen, and wood stagnation causes soil deficiency, so that the white atractylodes rhizome is used for tonifying spleen qi, so that soil can be kept out of wood, and nutrient and blood can be biochemically and actively generated; 7 medicines of angelica, tree peony bark, gardenia, tangerine peel, tuckahoe, dragon bone and oyster are used as adjuvant medicines; chinese angelica is sweet, pungent, bitter and warm, and can nourish blood and harmonize blood; cortex moutan is effective in clearing deficient fire in blood, and fructus Gardeniae is effective in clearing stagnated heat of liver and gallbladder, and directing heat downward; the dried orange peel is pungent, bitter and warm, regulates qi, promotes stagnation, eliminates dampness and phlegm; poria has effects in invigorating spleen, eliminating dampness, tranquilizing mind, strengthening spleen and stomach, and eliminating turbid dampness, so as to eliminate phlegm, promote qi and blood circulation, and relieve restlessness; os Draconis has effects of tranquilizing mind, arresting sweating, arresting spontaneous emission, and relieving stagnation of liver-qi; oyster can calm the nerves, calm the liver and subdue yang, and regulate emotion; 2 medicaments of honey-fried licorice root and mint are used as guiding medicaments; prepared licorice root, radix Glycyrrhizae Praeparata has the effects of invigorating qi, strengthening the middle warmer, relieving liver urgency, and harmonizing the other drugs; a little peppermint is added in the application for dispelling stagnated qi and penetrating and reaching the stagnated heat of the liver channel. The whole prescription has 15 medicines, all the medicines are used together, the liver and the spleen are synchronously adjusted, the dampness and the phlegm are eliminated, the middle-jiao is adjusted, the nerves are calmed, and the nutrition is dredged and applied. The main treatment is as follows: stagnation due to liver qi stagnation and spleen deficiency, incoordination between gallbladder and stomach, phlegm-dampness and blood stasis. Can be used for treating depression, anxiety, climacteric syndrome, neurasthenia, neurosis, hysteria, amnesia, insomnia, separation disorder (hysteria), premenstrual tension, acute and chronic gastritis, and gastroesophageal reflux, with syndrome differentiation of liver depression and spleen deficiency, incoordination between gallbladder and stomach, and phlegm dampness stagnation.
The traditional Chinese medicine composition provided by the invention is safe, quick in effect, good in treatment effect, free of toxic and side effects, easy to accept by patients, and capable of avoiding toxic and side effects caused by large-dose use of western medicines. Meanwhile, compared with the basic formula of the gallbladder warming decoction and the Danzhi Xiaoyao powder, the traditional Chinese medicine composition provided by the invention has a better treatment effect on depression caused by liver depression and spleen deficiency and excessive dampness.
Drawings
FIG. 1 is a graph showing the results of an open field test;
FIG. 2 is a graph showing the results of a tail overhang test; in comparison with the normal group, ** P<0.01, compared with the gallbladder warming decoction group, ## P<0.01; compared with the Danzhi Xiaoyao powder group, $ P<0.05；
FIG. 3 is a graph showing the results of a forced swim test; compared with the group of gallbladder-warming decoction, # P<0.05， ## P<0.01; compared with the Danzhi Xiaoyao powder group, $ P<0.05。
Detailed Description
The invention is described in detail below with reference to the drawings and specific examples, but the invention should not be construed as being limited thereto. The technical means used in the following examples are conventional means well known to those skilled in the art, and materials, reagents and the like used in the following examples can be commercially available unless otherwise specified.
Based on the pathogenesis characteristics of depression, liver depression, spleen deficiency and excessive dampness, the invention provides a traditional Chinese medicine composition for treating depression, which takes 'liver and spleen concoction, phlegm elimination, dampness transformation and middle regulation and tranquilization' as an entry point, and is prepared from the following raw materials in parts by weight: 6 to 20 portions of rhizoma pinelliae preparata, 6 to 20 portions of radix bupleuri, 6 to 20 portions of white peony root, 6 to 20 portions of bamboo shavings, 6 to 30 portions of immature bitter orange, 6 to 30 portions of fried rhizoma atractylodis macrocephalae, 6 to 20 portions of angelica, 6 to 20 portions of moutan bark, 6 to 20 portions of gardenia, 6 to 20 portions of dried orange peel, 6 to 20 portions of tuckahoe, 9 to 30 portions of keel, 9 to 30 portions of oyster, 3 to 15 portions of mint and 6 to 20 portions of honey-fried licorice root.
The traditional Chinese medicine composition is decocted in water for taking, one dose is taken every day, 2 times a day, once in the morning and at night, and is warm-taken 30-60 minutes after a meal, and 200-300 ml of the traditional Chinese medicine composition is taken every time.
The main indications of the Chinese medicinal composition are: depression due to liver depression and spleen deficiency with excessive dampness.
The efficacy is as follows: dispersing stagnated liver qi for relieving qi stagnation, regulating qi-flowing for eliminating dampness, clearing gallbladder and regulating stomach function
The main treatment is as follows: stagnation due to liver qi stagnation and spleen deficiency, incoordination between gallbladder and stomach, phlegm-dampness and blood stasis. Modern diseases are usually indicated for depression, anxiety, climacteric syndrome, neurasthenia, neurosis, hysteria, amnesia, insomnia, separation disorder (hysteria), premenstrual tension, acute and chronic gastritis, gastroesophageal reflux, etc., and the syndrome differentiation belongs to the patients with liver depression and spleen deficiency, incoordination between gallbladder and stomach, phlegm dampness and stasis.
Common symptoms are: low mood, decreased interest, oppression and discomfort in chest, restlessness, insomnia, irritability, tension, convulsion, anorexia, listlessness, pain, pale red tongue with thin and white coating, and wiry pulse.
The traditional Chinese medicine composition can be further prepared into pharmaceutically acceptable oral preparations, such as granules, capsules, tablets, oral liquid, syrup and the like.
The preparations for oral administration may contain conventional adjuvants such as binders, fillers, diluents, lubricants, disintegrants, coloring agents, flavoring agents and wetting agents, and the tablets may be coated if necessary. Optional fillers include cellulose, mannitol, lactose and other similar fillers. Alternative disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycolate. And optionally a lubricant such as magnesium stearate. An optional wetting agent includes sodium lauryl sulfate.
Oral liquid preparations are in the form of suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may include conventional additives such as suspending agents, for example, glycerol, syrup, methyl cellulose, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminum stearate gel, and the like; emulsifying agents, for example lecithin or acacia; non-aqueous carriers such as almond oil, fractionated coconut oil, propylene glycol or ethyl alcohol; preservatives, for example p-hydroxybenzoic acid methyl ester, propyl p-hydroxybenzoate or sorbic acid; conventional flavoring or coloring agents may also be included.
The following will explain the Chinese medicinal composition provided by the present invention with reference to specific examples.
Example 1
A traditional Chinese medicine composition for treating depression is composed of the following raw materials: 15g of rhizoma pinelliae preparata, 10g of radix bupleuri, 15g of radix paeoniae alba, 15g of caulis bambusae in taeniam, 20g of immature bitter orange, 20g of fried rhizoma atractylodis macrocephalae, 10g of angelica sinensis, 15g of cortex moutan radicis, 10g of gardenia, 20g of pericarpium citri reticulatae, 15g of poria cocos, 30g of dragon bone, 30g of oyster, 6g of mint and 10g of honey-fried licorice root.
Example 2
A traditional Chinese medicine composition for treating depression is composed of the following raw materials:
6g of rhizoma pinelliae preparata, 6g of radix bupleuri, 6g of radix paeoniae alba, 6g of caulis bambusae in taeniam, 6g of fructus aurantii immaturus, 6g of fried rhizoma atractylodis macrocephalae, 6g of angelica sinensis, 6g of cortex moutan, 6g of fructus gardeniae, 6g of pericarpium citri reticulatae, 6g of poria cocos, 9g of dragon bone, 9g of oyster, 3g of mint and 6g of honey-fried licorice root.
Example 3
A traditional Chinese medicine composition for treating depression is composed of the following raw materials:
20g of rhizoma pinelliae preparata, 20g of radix bupleuri, 20g of radix paeoniae alba, 20g of caulis bambusae in taeniam, 30g of immature bitter orange, 30g of fried rhizoma atractylodis macrocephalae, 20g of angelica sinensis, 20g of moutan bark, 20g of cape jasmine, 20g of dried orange peel, 20g of poria cocos, 30g of dragon bone, 30g of oyster, 15g of mint and 20g of honey-fried licorice root.
Example 4
A traditional Chinese medicine composition for treating depression is composed of the following raw materials:
12g of rhizoma pinelliae preparata, 12g of radix bupleuri, 18g of radix paeoniae alba, 18g of caulis bambusae in taeniam, 15g of immature bitter orange, 15g of fried rhizoma atractylodis macrocephalae, 18g of angelica, 18g of moutan bark, 15g of gardenia, 15g of dried orange peel, 18g of poria cocos, 20g of dragon bone, 20g of oyster, 8g of mint and 12g of honey-fried licorice root.
Example 5
A traditional Chinese medicine composition for treating depression is composed of the following raw materials:
18g of rhizoma pinelliae preparata, 10g of radix bupleuri, 12g of radix paeoniae alba, 12g of caulis bambusae in taeniam, 10g of immature bitter orange, 25g of fried rhizoma atractylodis macrocephalae, 12g of angelica sinensis, 18g of cortex moutan radicis, 12g of gardenia, 18g of pericarpium citri reticulatae, 12g of poria cocos, 25g of dragon bone, 18g of oyster, 12g of mint and 15g of honey-fried licorice root.
The traditional Chinese medicine compositions provided by the above embodiments 1 to 5 are all prepared according to the following method:
weighing purified pinellia tuber, radix bupleuri, radix paeoniae alba, caulis bambusae in taeniam, immature bitter orange, fried rhizoma atractylodis macrocephalae, angelica sinensis, cortex moutan, fructus gardeniae, pericarpium citri reticulatae, poria cocos, dragon bone, oyster shell, mint and radix glycyrrhizae preparata for later use;
mixing the weighed medicinal materials, adding water with an amount which is 8 times of the total amount of the medicinal materials for the first time, decocting for 1.5h, filtering, collecting the first decoction, adding water with an amount which is 6 times of the total amount of the medicinal materials into the filter residue, decocting for 1.5h, filtering, collecting the second decoction, and mixing the two decoctions to obtain the Chinese medicinal composition.
Example 6
The traditional Chinese medicine composition for treating depression is different from the traditional Chinese medicine composition in the embodiment 1 only in the preparation method, and specifically comprises the following steps:
weighing purified pinellia tuber, radix bupleuri, white peony root, bamboo shavings, immature bitter orange, stir-fried bighead atractylodes rhizome, chinese angelica, tree peony bark, cape jasmine fruit, dried orange peel, poria cocos, dragon bone, oyster shell, mint and honey-fried licorice root for later use;
mixing the weighed medicinal materials, adding water with an amount which is 8 times of the total amount of the medicinal materials for the first time, decocting for 1.0h, filtering, collecting the first decoction, adding water with an amount which is 6 times of the total amount of the medicinal materials into the filter residue, decocting for 1.0h, filtering, collecting the second decoction, and mixing the two decoctions to obtain the Chinese medicinal composition.
Example 7
A traditional Chinese medicine granule for treating depression is prepared according to the following method:
weighing 15g of rhizoma pinelliae preparata, 10g of radix bupleuri, 15g of radix paeoniae alba, 15g of caulis bambusae in taeniam, 20g of immature bitter orange, 20g of fried rhizoma atractylodis macrocephalae, 10g of angelica sinensis, 15g of moutan bark, 10g of gardenia, 20g of dried orange peel, 15g of poria cocos, 30g of dragon bone, 30g of oyster, 6g of mint and 10g of honey-fried licorice root;
mixing the weighed medicinal materials, adding water with the amount which is 8 times of the total amount of the medicinal materials for the first time, decocting for 1.0 hour, filtering, collecting a first decoction, adding water with the amount which is 6 times of the total amount of the medicinal materials into filter residues, decocting for 1.0 hour, filtering, collecting a second decoction, combining the two decoctions, concentrating at 50 ℃, to a relative density of 1.10 (70 ℃), standing, centrifuging, taking supernate, concentrating to a relative density of 1.25 (70 ℃), adding sugar powder with the amount which is 0.5 times of the total weight of the supernate and soluble starch with the amount which is 1.5 times of the total weight of the supernate into the obtained concentrate, mixing uniformly, granulating, drying at 70 ℃ by arranging a hot air circulation oven until the water content is about 6%, grading, and packaging to obtain the granular medicament for treating the depression. Packaging specification: 15 g/bag and 10 bags/box.
Experimental example 1
1. Laboratory animals and groups
70 SPF male ICR mice with the weight of 18-20 g and the weight of 6-8 w are bred in an environment with 24h light and shade cycle by freely eating and drinking water at the temperature of 25 +/-2 ℃ and the relative humidity of 40-60 percent for 12h in each day and night.
2. Method of producing a composite material
After the mice are fed for 3-7 days adaptively, the mice are randomly divided into a normal group (normal saline), a fluoxetine group (2 g/kg. D), a gallbladder warming decoction group (crude drug amount 31.7 g/kg. D), a Danzhi Xiaoyao san group (crude drug amount 37 g/kg. D), a high-dose group (crude drug amount 120.6 g/kg. D) in example 1, a medium-dose group (crude drug amount 60.3 g/kg. D) in example 1 and a low-dose group (crude drug amount 30.15 g/kg. D) in example 1, the normal group is subjected to the normal saline intragastric administration, 10 mice in each group are continuously administered for 15 days, and the behavioural tests including an Open Field Test (OFT), a Tail Suspension Test (TST) and a Forced Swimming Test (FST) are performed 1h after the last administration.
Wherein, the medicine composition of the gallbladder warming decoction is as follows: 15g of rhizoma pinelliae preparata, 15g of caulis bambusae in taeniam, 20g of fried immature bitter orange, 20g of dried orange peel, 15g of poria cocos and 10g of honey-fried licorice root.
The Danzhi Xiaoyao powder comprises the following components: 10g of radix bupleuri, 10g of angelica sinensis, 15g of fried white peony root, 15g of poria cocos, 20g of fried bighead atractylodes rhizome, 15g of moutan bark, 10g of raw gardenia, 10g of honey-fried licorice root and 5g of mint.
2.1 Open Field Test (OFT)
The method is carried out in a quiet environment, the animals are placed in small squares with the height of 30-40cm, the side length of the bottom is 100cm, the inner wall of the black color is divided into 4 cells with the bottom edge of 25cm, the animals are placed in the center of the bottom surface of the box, the shooting and the timing are carried out simultaneously, the operation is stopped after 5min, and the inner wall and the bottom surface of the box are cleaned, so that the influence of information (such as the excrement, urine and smell of the animals) left by the animals on the next test result is avoided. The number of autonomic activity of the mice was determined during the test period.
2.2 Tail Suspension Test (TST)
Fixing the rat tail 2cm behind the rat tail in a horizontal position by using an adhesive tape to enable the rat tail to be in an inverted hanging state, keeping the head about 6-8 cm away from the lower horizontal plane, and recording the accumulative and motionless time of the animal 4min later within 6 min.
2.3 Forced Swimming Test (FST)
The rats are placed in a glass jar with the height of 40cm and the diameter of 30cm and containing 25 ℃ tap water, the water depth can be adjusted, if the rear feet of the rats just touch the bottom of the jar but are not enough to support the body, the accumulated motionless time of the animals within 6min after 4min is recorded.
3. Results
The number of independent activities of the mice measured in the OFT represents the independent activity ability of the mice, and the number of independent activities of the mice after administration of each group of the drugs is not different, which indicates that the mice are normal mice and the independent activity ability of the mice is not affected after administration of the drugs, as shown in fig. 1.
TST is a technique in which a mouse, after hanging its tail, attempts to escape but cannot escape, thereby abandoning struggling and entering a characteristic depressed immobility state, which is called a despair state as a typical "immobility state" exhibited by an animal, and which is evaluated during an experiment by recording the immobility time of the animal over a certain period of time, the longer the immobility time, the more severe the degree of depression. The results show that the low and medium dose groups of example 1 can significantly shorten the immobility time of mice, as shown in fig. 2.
The depressed state of the mice was also assessed in FST by recording the immobility time that the mice attempted to escape in a confined environment but were unable to escape, thereby giving up struggling to go into immobility, the longer the immobility time, the more severe the depression. The results show that the low dose group of example 1 significantly reduced immobility time in mice, see figure 3.
As can be seen from the data of OFT, TST and FST, the low and medium dose groups in example 1 have better effects than the Wendan decoction group and the Danzhi Xiaoyao powder group, but the low dose in example 1 is finally determined as the optimal dose considering the influence of the concentration of the drug on the administration, the concentration of the drug is low, the animal acceptance is high and the animal resistance is not resisted.
Experimental example 2
Clinical data
1. Source of cases
60 patients were selected for outpatient service at the first subsidiary hospital of Henan university of traditional Chinese medicine, the Hospital of Henan province, and the third subsidiary hospital of Henan university of traditional Chinese medicine from 2016 (1 month) to 2020 (8 months). The subjects were randomly selected to enter treatment groups and control groups, each group had 30 patients, treated for 35 days, screened separately, evaluated for efficacy index scales at baseline, treatment 7, 14, 21, 28, 35 days, and compared for efficacy, onset time, and adverse reactions after administration.
2. Diagnostic criteria
2.1 Western diagnostic standards
The Western diagnosis standard refers to the diagnosis standard about depression in the third edition (CCMD-3) of Chinese Classification scheme and diagnosis Standard for mental diseases: the depression is characterized by a depressed mood, manifested as stuffiness or a lack of desire to have pain, and persisting for two weeks, which is additionally accompanied by four of the following symptoms:
(1) The vigor obviously declines, and the continuous fatigue feeling is not caused;
(2) Self-evaluation is too low, or self-liability, or feelings of guilt;
(3) Psychomotor retardation or agitation;
(4) The interest of the daily life is lost, and the daily life is unhappy;
(5) The thoughts of dying or suicide repeatedly appear;
(6) Difficulty in association, and remarkably reduced self-thought ability;
(7) Loss of appetite and significant weight loss;
(8) The libido is obviously declined;
(9) Insomnia or hypersomnia.
Severity criteria: the social function is damaged, causing pain or bad results for the self.
The disease course standard is as follows:
(1) Compliance with symptom and severity criteria has continued for at least 2 weeks.
(2) Some symptoms of schizolysis may be present, but not consistent with the diagnosis of schizophrenia. If the symptom criteria for schizophrenia are met at the same time, the criteria for a depressive episode are met for at least 2 weeks after the schizophrenia is alleviated.
Exclusion criteria: eliminating organic mental disorder, or mental disorder caused by mental active substance and non-addictive substance.
2.2 Western medicine scoring Standard
Using Hamilton Depression Scale (HAMD) scoring method.
The HAMD project adopts a 3-5 grade grading method with 0-4 points: no at 0, mild at 1, moderate at 2, severe at 3, and very severe at 4.
Depressed mood: 0 minute: none; 1 minute: appeal only when asked; and 2, dividing: spontaneously expressed in a conversation; and 3, dividing: the emotion can be revealed from expressions, gestures, sounds or crying without speech; and 4, dividing: the patient's spontaneous language, and thus non-verbal expression (action, expression), almost completely expresses this emotion.
Guilty: 0 minute: none; 1 minute: the person is responsible for oneself and feels that the person is tired of others; and 2, dividing: think that oneself crimes, or think past mistake and mistake repeatedly; and 3, dividing: the current diseases are considered to be the most wrong punishment or the guilt; and 4, dividing: recklessly thought of guilt accompanied by accountability or threatening hallucinations
Suicide: 0 minute: none; 1 minute: feeling alive has no meaning; and 2, dividing: hope that oneself has died, or think about things that are related to death frequently; and 3, dividing: negative concepts (suicidal thoughts); and 4, dividing: the recklessly thought of the nefarious is accompanied by a disclaimer or a threatening hallucination.
Difficulty in falling asleep: 0 minute: none; 1 minute: the chief complaints sometimes have difficulty falling asleep, namely that the patient still cannot fall asleep after getting out of bed for half an hour; and 2, dividing: the chief complaints are that it is difficult to fall asleep every night.
Not deep sleep: 0 minute: none; 1 minute: light, more nightmare; and 2, dividing: awakening (excluding going to the toilet) in the middle of the night (before 12 nights).
Early waking: 0 minute: none; 1 minute: the people can wake up earlier than usual for 1 hour, but can fall asleep again; and 2, dividing: can not be re-hung after early waking.
Work and interest: 0 minute: none; 1 minute: the question is told when asked; and 2, dividing: spontaneously express the loss of interest in activities, work or learning directly or indirectly, such as feeling inexperienced, unrestrained, unable to persist or forced to work or move; and 3, dividing: the activity time is reduced or the effect is reduced, and the hospitalized patients have less than 3 hours of working or recreational activities in the sickroom every day; and 4, dividing: the current disease causes the patient to stop working, and the patient can not complete the daily routine of the ward without taking part in any activities or being helped by others.
Delaying: 0 minute: none; 1 minute: mild delays were found in mental examinations; and 2, dividing: the mental examination finds obvious retardation; and 3, dividing: difficulty in performing mental examinations; and 4, dividing: the question (stupor) cannot be answered at all.
The leap: 0 minute: none; 1 minute: some uneasiness is shown during examination; and 2, dividing: obvious unsteadiness of heart-mind or small movements; and 3, dividing: the patient can not sit still and stands up in the examination; and 4, dividing: rub the hand, bite the fingers, pull the hair, and hand over the lips.
Psychogenic anxiety: 0 minute: none; 1 minute: ask for brief; and 2, dividing: (ii) is expressed spontaneously; and 3, dividing: facial expressions and speech streams are showing significant anxiety; and 4, dividing: with obvious fear.
Somatic anxiety: refers to the physiological symptoms of anxiety, including dry mouth, abdominal distension, diarrhea, excoriation, abdominal pain, palpitations, headache, hyperventilation and sigh, as well as frequent urination and sweating. 0 minute: none; 1 minute: mild; and 2, dividing: moderate, with positive above symptoms; and 3, dividing: severe, the above symptoms are severe, affecting the symptoms or requiring treatment for 4 points: severely affecting life and activities.
Gastrointestinal symptoms: 0 minute: none; 1 minute: the appetite is reduced, but the self-help eating is not encouraged by others; and 2, dividing: eating may be prompted or requested by others or may require the application of purgatives or digestants.
Systemic symptoms: 0 minute: none; 1 minute: heaviness in the limbs, back or neck, back pain, headache, muscle pain, general fatigue or lassitude; and 2, dividing: the symptoms are significant.
Sexual symptoms: hyposexuality and irregular menstruation. 0 minute: none; 1 minute: mild; and 2, dividing: (ii) severe; and 3, dividing: not affirmed, or the item is not matched (not included in the total score) to the subject.
Suspicion of disease: 0 minute: none; 1 minute: excessive attention to the body; and 2, dividing: repeatedly considering health problems; and 3, dividing: hypochondriasis; and 4, dividing: with the suspicion of a fantasy party.
Weight loss: 0 minute: none; 1 minute: the weight is reduced by more than 1 jin within one week; 2: the weight is reduced by more than 2 jin in one week
Self-learning force: 0 minute: none; 1 minute: knowing that the patient is ill and shows melancholy; and 2, dividing: knowing that the patient has a disease, but the patient is suffered from poor daily diet, environmental problems, busy work, virus infection or rest requirement and the like; and 3, dividing: completely deny the disease.
2.3 Chinese medicine diagnosis Standard
According to the Chinese medicine diagnosis standard and syndrome standard formulated in the 'standard for diagnosis and treatment effect of Chinese medicine syndrome-depression disease' in 1995. The basis of diagnosis is as follows: (1) Depression, lassitude, chest distress and hypochondrium distention, frequent sighing, or poor appetite, insomnia, dreaminess, irritability, crying, etc.; (2) irritability and excessive anxiety. Sadness. Emotional disorders such as worry and worry; (3) Organic diseases can be eliminated by various system examinations and laboratory examinations.
2.4, syndrome differentiation Standard of traditional Chinese medicine
Refer to SFDA (guide principles of clinical research on new Chinese medicines) (2005 edition), TCM administration (TCM) clinical pathway of TCM (depression attacks) and TCM diagnosis and treatment schemes (2017 edition).
Definition of patients with liver stagnation, spleen deficiency and phlegm stagnation:
the main symptoms are: low mood, distending and uncomfortable feeling in the chest and hypochondrium, suspicion of much anxiety and frequent sighing;
the secondary symptoms are as follows: emaciation, anorexia, insomnia, amnesia, chest distress, gastric distention, abdominal pain, abdominal distention, loose stool, discomfort in pharynx, irritability, belch, singultus, restlessness, and pain;
tongue manifestation: pale-red tongue with white and greasy coating;
the pulse condition: and (4) string sliding.
The traditional Chinese medicine composition meets the diagnosis standards of western medicine depression and traditional Chinese medicine depression, has 3 items of main symptoms and 3 items of secondary symptoms of liver depression, spleen deficiency and phlegm stagnation in traditional Chinese medicine, and can be diagnosed as depression with liver depression, spleen deficiency and phlegm stagnation by referring to tongue symptoms and pulse symptoms.
2.5 Chinese medicine symptom scoring standard
Refer to the "clinical research guidelines for new Chinese drugs
The main symptoms are:
emotional depression: 0 minute: none; and 2, dividing: sometimes it happens; and 4, dividing: the method can be frequently used, but can be automatically controlled; and 6, dividing into: frequently, the treatment needs to be taken.
And (3) committing to cry: 0 minute: none; and 2, dividing: sometimes, the mother bends and wants to cry; and 4, dividing: frequent flexing and crying can be controlled; 6 min: the person who attempts to cry cannot control the operation.
Good tai xiu: 0 minute: none; and 2, dividing: occasionally, the patient feels the taiji; and 4, dividing: doing the work when the patient is in the rest; and 6, dividing into: the taiji acts frequently.
Fullness in the chest and hypochondrium: 0 minute: none; and 2, dividing: the occasional occurrence can relieve the accident by itself; and 4, dividing: the chest and hypochondrium are full of 2 hours every day; 6 min: the chest and hypochondrium are continuously full.
The secondary symptoms are as follows:
amnesia: 0 minute: normal memory; 1 minute: forgetting sometimes; and 2, dividing: are often forgotten; and 3, dividing: often forget to work and influence work.
Insomnia: 0 minute: normal; 1 minute: easy to wake up, or sleep but not hard. Early morning waking does not affect work; and 2, dividing: the sleep time is less than 4 hours every day, and normal work is difficult to adhere to; and 3, dividing: the user can not sleep all night and is difficult to insist on normal work.
Impatience and irritability: 0 minute: none; 1 minute: impatience of mood; and 2, dividing: the patient is easy to be irritated and angry; and 3, dividing: the medicine is administered more than 10 times daily.
Belching: 0 minute: none; 1 minute: more than 3 times a day; and 2, dividing: 4-9 times daily; and 3, dividing: the preparation is administered more than 10 times daily.
Hiccup: 0 minute: none; 1 minute: more than 3 times a day; and 2, dividing: 4-9 times daily; and 3, dividing: the preparation is administered more than 10 times daily.
Restlessness in sitting and lying: 0 minute: none; and 2, dividing: restlessness in sitting and lying.
Foreign body sensation in pharynx: 0 minute: none; and 2, dividing: has foreign body sensation.
Body pain: 0 minute: none; and 2, dividing: body pain.
Chest distress: 0 minute: none; 1 minute: the occasional occurrence can relieve the accident by itself; and 2, dividing: suffocating in the stomach for about 2 hours every day; and 3, dividing: and the solution is continued.
3. Inclusion criteria
(1) Meets the diagnosis standard of the western medicine depression;
(2) The diagnosis standard of the traditional Chinese medicine depression syndrome and the diagnosis standard of the syndrome of stagnation of liver-qi and spleen-deficiency and phlegm obstruction are met;
(3) HAMD score is more than or equal to 7 points and less than or equal to 24 points;
(4) The age is more than or equal to 18 years and less than or equal to 75 years;
(5) The mind is clear, the language barrier is avoided, the symptoms of the user can be correctly expressed, and the user can be informed to agree;
(6) The patient compliance is high, and the study can be completed cooperatively.
The selected cases must meet the above 6 inclusion criteria
4. Exclusion criteria
(1) Patients who take antidepressant medicaments within 1 month before selection;
(2) Major depressive disorder patients or those with a severe suicidal tendency;
(3) Those with secondary depressive episodes or with severe psychotic symptoms;
(4) Bipolar affective disorder or treatment refractory depression;
(5) Patients under 18 years of age or over 75 years of age, pregnant women or lactating women;
(6) Patients with serious primary diseases of all systems or patients with cardiac, hepatic and renal insufficiency;
(7) People allergic to known research drug ingredients.
If the above 1 condition is met, it is excluded
5. Criteria for case rejection and shedding
(1) Patients have poor compliance and do not take medicines according to the regulations;
(2) Serious adverse reactions and other conditions occur in the medicine taking process, other related treatments need to be received, the medicine can not be taken continuously according to the regulation, or the disease condition of a patient is further worsened in the test process, and other treatments are needed;
(3) Other drugs taken by oneself during the taking of the medicine may affect the observation result;
(4) Self-quit for some reason;
(5) Failure to accept a follow-up for some reason;
6. treatment regimens
6.1, treatment grouping:
patients were randomized into 2 groups, 30 control groups and 30 treatment groups.
6.2 methods of treatment
Treatment groups: when the traditional Chinese medicine composition provided by the embodiment 1 of the invention is used for treatment, the prescription mainly comprises the following components: 15g of rhizoma pinelliae preparata, 10g of radix bupleuri, 15g of radix paeoniae alba, 15g of caulis bambusae in taeniam, 20g of immature bitter orange, 20g of fried rhizoma atractylodis macrocephalae, 10g of angelica sinensis, 15g of moutan bark, 10g of cape jasmine, 20g of dried orange peel, 15g of poria cocos, 30g of dragon bone, 30g of oyster, 6g of mint and 10g of honey-fried licorice root. The traditional Chinese medicine composition decoction is taken by patients with liver depression, spleen deficiency and phlegm stagnation type depression for treatment, one dose is taken every day, the decoction is taken by water, 2 times a day, one time is taken in the morning and at night, and the decoction is taken by warming 30 to 60 minutes after a meal, and 200 to 300ml of the decoction is taken every time. 7 days is a course of treatment, and the curative effect is counted for 5 courses of treatment.
Control group: paroxetine hydrochloride tablet (20 mg/tablet, manufactured by Beijing Fuyuan medicine Co., ltd.) is taken after meal at a dose of 20 mg/time and 1 time/day. 7 days is a course of treatment, and the total curative effect is counted for 5 courses of treatment.
7. Therapeutic index and evaluation criteria
7.1 Western medicine curative effect index
HAMD total score minus score = baseline HAMD total score-post-treatment HAMD total score;
gross HAMD score reduction = [ (baseline HAMD gross score-post-treatment HAMD gross score) ÷ baseline HAMD gross score ] × 100% (refer to the therapeutic standard of depression made by the chinese medical society in 1984)
(1) Evaluation criteria:
and (3) healing: the HAMD score is less than or equal to 7 points;
the remarkable progress is that: the reduction rate is more than or equal to 50 percent;
the improvement is as follows: the reduction rate is more than or equal to 25 percent;
and (4) invalidation: the reduction rate is less than 25 percent,
significant = recovery + significant improvement + progress.
(2) The evaluation standard of the curative effect is as follows: the score of decrease and the score of decrease in HAMD at the end of treatment were used as the evaluation criteria for efficacy, and the end point of evaluation was at the end of day 35.
7.2 evaluation index of traditional Chinese medicine symptom curative effect
The traditional Chinese medicine symptom total score minus value = baseline traditional Chinese medicine symptom total score-traditional Chinese medicine syndrome total score after treatment;
the total traditional Chinese medicine symptom reduction rate = [ (baseline traditional Chinese medicine symptom total rate-total traditional Chinese medicine symptom after treatment ÷ baseline traditional Chinese medicine symptom total rate) ] × 100%; (evaluation Using nimodipine method)
(1) And (4) evaluation standard:
and (3) clinical control: clinical symptoms and physical signs disappear or basically disappear, and the syndrome score is reduced by more than or equal to 90 percent;
the effect is shown: the clinical symptoms and physical signs are obviously improved, and the syndrome integral is reduced by more than or equal to 70 percent;
the method has the following advantages: the clinical symptoms and physical signs are improved, and the syndrome integral is reduced by more than or equal to 30 percent;
and (4) invalidation: the clinical symptoms and physical signs are not obviously improved or even aggravated, and the syndrome integral is reduced by less than or equal to 30 percent.
Total effective = clinical control + significant + effective
The evaluation standard of curative effect is as follows: the reduction rate of the traditional Chinese medicine symptoms at the end of treatment is taken as a curative effect evaluation standard, and the evaluation endpoint is 35 days at the end.
8. Evaluation of therapeutic Effect
Of 60 patients, 22 men and 38 women, the ratio of men to women was 1: 1.73, the age was 18 to 75 years, the course of disease was 35 to 10 years, and the treatment period of 7 days was one treatment period, and the treatment effect was mainly observed within 35 days (five treatment periods).
9. Results
The treatment results were evaluated by Western medicine HAMD score reduction, and are shown in Table 1.
TABLE 1 HAMD Subtraction efficacy of each group
| Grouping | Number of examples | Healing (example) | Remarkable progress (example) | Progress (example) | Invalid (example) | Significant effect (%) |
| Treatment group | 30 | 6 | 16 | 4 | 4 | 86.67 |
| Control group | 30 | 4 | 14 | 6 | 6 | 80.00 |
The treatment results were evaluated by the efficacy of the Chinese medical symptom scores, as shown in Table 2.
TABLE 2 Scoring curative effects of Chinese medicine symptoms of each group
Compared with the prior art, the total effective rate and the clinical control rate of the treatment group are obviously higher than those of the control group at the end of treatment no matter the HAMD (hepatic cirrhosis syndrome) reduction value of the western medicine is evaluated or the Chinese medicine symptom reduction value is evaluated, and the treatment effect of the treatment group on the liver depression and spleen deficiency dampness type depression is obviously better than that of the control group.
Safety is as follows: during the administration period, the treatment group has few adverse reactions, and the adverse reactions such as nausea, abdominal distension, diarrhea and the like are occasionally and are not obvious; the control group has more adverse reactions, and symptoms such as nausea, vomiting, anorexia, palpitation, diarrhea, abdominal distension and the like, and the adverse reactions of the treatment group are obviously less than those of the control group on the whole.
In conclusion, the traditional Chinese medicine composition provided by the invention has the advantages of obvious and stable curative effect on depression caused by liver depression, spleen deficiency and phlegm stagnation, safe medication and great clinical significance, and is worthy of popularization and application.
While preferred embodiments of the present invention have been described, additional variations and modifications in those embodiments may occur to those skilled in the art once they learn of the basic inventive concepts. Therefore, it is intended that the appended claims be interpreted as including preferred embodiments and all such alterations and modifications as fall within the scope of the invention.
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.
Claims (10)
1. A traditional Chinese medicine composition for treating liver depression and spleen deficiency and dampness excess type depression is characterized by being prepared from the following raw materials in parts by weight: 6 to 20 portions of rhizoma pinelliae preparata, 6 to 20 portions of radix bupleuri, 6 to 20 portions of white peony root, 6 to 20 portions of bamboo shavings, 6 to 30 portions of immature bitter orange, 6 to 30 portions of fried rhizoma atractylodis macrocephalae, 6 to 20 portions of angelica, 6 to 20 portions of moutan bark, 6 to 20 portions of gardenia, 6 to 20 portions of dried orange peel, 6 to 20 portions of tuckahoe, 9 to 30 portions of dragon bone, 9 to 30 portions of oyster, 3 to 15 portions of mint and 6 to 20 portions of honey-fried licorice root.
2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight: 15 parts of rhizoma pinelliae preparata, 10 parts of radix bupleuri, 15 parts of radix paeoniae alba, 15 parts of caulis bambusae in taeniam, 20 parts of immature bitter orange, 20 parts of fried rhizoma atractylodis macrocephalae, 10 parts of angelica sinensis, 15 parts of cortex moutan radicis, 10 parts of fructus gardeniae, 20 parts of pericarpium citri reticulatae, 15 parts of poria cocos, 30 parts of dragon bone, 30 parts of oyster, 6 parts of mint and 10 parts of honey-fried licorice root.
3. A method for preparing the traditional Chinese medicine composition of claim 1 or 2, which is characterized by comprising the following steps:
weighing rhizoma Pinelliae, bupleuri radix, radix Paeoniae alba, caulis Bambusae in Taenia, fructus Aurantii Immaturus, parched Atractylodis rhizoma, radix Angelicae sinensis, cortex moutan, fructus Gardeniae, pericarpium Citri Tangerinae, poria, os Draconis, concha Ostreae, herba Menthae and radix Glycyrrhizae Preparata according to weight parts;
mixing the weighed medicinal materials, adding water, decocting, and collecting decoction to obtain the traditional Chinese medicine composition.
4. The preparation method according to claim 3, wherein the specific operation process of decocting with water comprises the following steps: adding water which is 6-8 times of the total amount of the medicinal materials into the mixed medicinal materials, decocting for 2-3 times, 1.0-1.5 h each time, combining decoction, and filtering.
5. Use of the Chinese medicinal composition of claim 1 or 2 in the preparation of a medicament for the treatment of depression.
6. The use of claim 5, wherein the depression is caused by liver depression and spleen deficiency, incoordination between the gallbladder and stomach, phlegm-dampness and blood stasis.
7. A medicament for treating depression, which is characterized in that the medicament comprises the traditional Chinese medicine composition as claimed in claim 1 or 2 and pharmaceutically acceptable auxiliary materials or carriers.
8. The medicament of claim 7, wherein the medicament is in the form of granules, tablets, decoction, capsules or syrup.
9. A traditional Chinese medicine granule for treating depression caused by liver depression and spleen deficiency and excessive dampness, which is characterized by comprising the traditional Chinese medicine composition of claim 1 or 2 and pharmaceutically acceptable auxiliary materials.
10. A method for preparing the traditional Chinese medicine granule of claim 9, which is characterized by comprising the following steps:
weighing rhizoma Pinelliae, bupleuri radix, radix Paeoniae alba, caulis Bambusae in Taenia, fructus Aurantii Immaturus, parched Atractylodis rhizoma, radix Angelicae sinensis, cortex moutan, fructus Gardeniae, pericarpium Citri Tangerinae, poria, os Draconis, concha Ostreae, herba Menthae and radix Glycyrrhizae Preparata according to weight parts;
mixing the weighed medicinal materials, adding water, decocting, collecting decoction, concentrating at 50 deg.C and-0.06-0.08 mpa, adding sugar powder and soluble starch into the obtained concentrate, granulating, drying, and grading.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211310613.6A CN115501305B (en) | 2022-10-25 | 2022-10-25 | Traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211310613.6A CN115501305B (en) | 2022-10-25 | 2022-10-25 | Traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115501305A true CN115501305A (en) | 2022-12-23 |
| CN115501305B CN115501305B (en) | 2023-11-21 |
Family
ID=84512853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211310613.6A Active CN115501305B (en) | 2022-10-25 | 2022-10-25 | Traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115501305B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116173173A (en) * | 2023-03-24 | 2023-05-30 | 河北医科大学第一医院 | Traditional Chinese medicine composition for treating depression and preparation method thereof |
| CN116920052A (en) * | 2023-09-06 | 2023-10-24 | 南京市中医院 | Traditional Chinese medicine composition for treating primary sicca syndrome with depression and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102139086A (en) * | 2011-04-09 | 2011-08-03 | 河南中医学院 | Traditional Chinese medicine for treating liver constraint and spleen deficiency type post-stroke depression |
| CN103933487A (en) * | 2014-05-09 | 2014-07-23 | 厦门大学 | Compound traditional Chinese medicament for treating depression |
| CN106880776A (en) * | 2017-02-24 | 2017-06-23 | 威海康辉生物科技有限公司 | A kind of Chinese medicine composition for treating insomnia |
-
2022
- 2022-10-25 CN CN202211310613.6A patent/CN115501305B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102139086A (en) * | 2011-04-09 | 2011-08-03 | 河南中医学院 | Traditional Chinese medicine for treating liver constraint and spleen deficiency type post-stroke depression |
| CN103933487A (en) * | 2014-05-09 | 2014-07-23 | 厦门大学 | Compound traditional Chinese medicament for treating depression |
| CN106880776A (en) * | 2017-02-24 | 2017-06-23 | 威海康辉生物科技有限公司 | A kind of Chinese medicine composition for treating insomnia |
Non-Patent Citations (2)
| Title |
|---|
| 孙春林;刘昌海;: "中西医结合治疗高血压病伴焦虑症状60例临床观察", 新中医, no. 01, pages 60 - 61 * |
| 宋光明;杨娟;: "丹栀逍遥散加味治疗卒中后抑郁的疗效观察", 天津中医药, no. 04, pages 296 - 298 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116173173A (en) * | 2023-03-24 | 2023-05-30 | 河北医科大学第一医院 | Traditional Chinese medicine composition for treating depression and preparation method thereof |
| CN116920052A (en) * | 2023-09-06 | 2023-10-24 | 南京市中医院 | Traditional Chinese medicine composition for treating primary sicca syndrome with depression and preparation method and application thereof |
| CN116920052B (en) * | 2023-09-06 | 2024-04-19 | 南京市中医院 | Traditional Chinese medicine composition for treating primary sicca syndrome with depression and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115501305B (en) | 2023-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115501305A (en) | Traditional Chinese medicine composition for treating liver depression and spleen deficiency damp excess type depression and application thereof | |
| CN100493597C (en) | Medicine composition for treating neurosis | |
| CN101810787B (en) | Chinese medicinal composition for treating dysphoria and preparation method thereof | |
| CN101711853B (en) | Traditional Chinese medicine composition for treating symptoms of bradycardia and preparation method thereof | |
| CN109646526B (en) | Traditional Chinese medicine composition for treating depression and preparation method thereof | |
| CN108853223A (en) | A kind of intelligence system emplastrum and preparation method thereof for treating children's real example | |
| CN104383421A (en) | Pharmaceutical preparation for treating insomnia and dreaminess | |
| CN114224998A (en) | Traditional Chinese medicine composition for treating spleen-kidney yang deficiency type functional dyspepsia, preparation and application | |
| CN103230457A (en) | Traditional Chinese medicine composition for treating viral myocarditis and preparation method and use thereof | |
| CN103495108B (en) | Medicine for treating chronic hypotension and preparation method for medicine | |
| CN107137504B (en) | Health food for improving sleep and enhancing immunity | |
| CN101804184B (en) | Traditional Chinese medicine composition for treating chest distress and preparation method thereof | |
| CN104689151A (en) | Traditional Chinese medicine composition for treating diabetes and use of composition | |
| CN110859949A (en) | Traditional Chinese medicine composition for treating infantile transient tic disorder and preparation method and application thereof | |
| CN100998744A (en) | Chinese patent drug for treating infantile hyperkinetic syndrome | |
| CN108853411A (en) | A kind of intelligence system emplastrum and preparation method thereof for treating the various cough of children | |
| CN115779031B (en) | Traditional Chinese medicine composition for treating insomnia | |
| Singh et al. | Concept of dermatological disorders in Ayurveda | |
| CN116920052B (en) | Traditional Chinese medicine composition for treating primary sicca syndrome with depression and preparation method and application thereof | |
| CN114191513B (en) | Traditional Chinese medicine composition for treating damp-heat type obesity | |
| CN1059121C (en) | Chinese medicine capsule for curing pulmonary tuberculosis | |
| CN116059302B (en) | Traditional Chinese medicine composition for treating gastrointestinal motility diseases and preparation method and application thereof | |
| CN113521159B (en) | Qi and blood tonifying, body resistance strengthening, white blood increasing and face beautifying cream and preparation method thereof | |
| CN102441103A (en) | Medicine for treating insomnia | |
| CN105434976B (en) | Anti-fatigue traditional Chinese medicine compound, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |